AETIONOMY

Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy
AETIONOMY logo

FACTS & FIGURES

Start Date
End Date
Call
IMI1 - Call 8
Grant agreement number
115568

Contributions
IMI Funding
7 993 234
EFPIA in kind
8 021 460
Other
1 854 480
Total Cost17 869 174

Summary

Today, diseases are defined largely on the basis of their symptoms, yet while two patients may share the same diagnosis, the underlying causes of their symptoms may be very different. This means that a treatment that works in one patient may prove ineffective in another. There is now broad recognition that a new approach to disease classification is needed, and that is where the AETIONOMY project comes in. It will pave the way towards a new approach to the classification of neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s diseases, thereby improving drug development and increasing patients’ chances of receiving a treatment that works for them.

Dementia affects 44 million people globally, and that figure is set to rise to 135 million by 2050, mostly due to the ageing of the population. Alzheimer’s disease is the most common form of dementia, accounting for between 60% and 80% of all cases. Meanwhile an estimated 4-6 million people globally suffer from Parkinson’s disease. There is no cure for these devastating diseases, and caring for patients as their disease progresses represents an immense burden for family members, carers, and health and social care systems.

Developing new treatments for brain disorders takes longer and costs more than for other disease areas. When it comes to Alzheimer’s and Parkinson’s diseases, the way these diseases are classified is hampering efforts to develop effective, targeted treatments.

Currently, diseases are defined largely on the basis of the patient’s symptoms and where they occur in the body. Many are classified based simply on the name of the doctor or researcher who first discovered or described the disease – this is the case for both (Alois) Alzheimer’s and (James) Parkinson’s diseases.

Rethinking classification: from effect to cause

There is growing evidence that while two patients may be classified as having the same disease, the genetic or molecular causes of their symptoms may be very different. This means that a treatment that works in one patient will prove ineffective in another. In other cases, diseases that are currently defined as separate conditions may share a common molecular basis. There is therefore now broad recognition that the way diseases are classified needs to change, and the field of neurodegenerative diseases in particular is considered to be ripe for a rethink.

This is an ambitious project: there are few meaningful correlations or causal links between disease features at the molecular level (e.g. genetic mutations or gene activity), features at the tissue / organ level (e.g. changes in the brain), and features at the clinical level (including symptoms and the results of imaging scans). Even in cases where the disease runs in families, it is not uncommon to find family members who share the same genetic mutation but have different clinical symptoms. For most patients, the disease is simply described as ‘idiopathic’, meaning the cause is unknown.

Nevertheless, the literature, public databases, and private companies have vast amounts of data that could be used to pave the way for a better classification of patients, based on underlying causes instead of symptoms. However, we lack an efficient way to generate new knowledge from these resources, and that is where the AETIONOMY project comes in.

The AETIONOMY team will tackle the problem of how to dynamically organise and structure different types of data (ranging from molecular data to information on symptoms) and how to apply this knowledge to construct a new classification of patient groups based on the underlying causes of their disease. Achieving this is far beyond the scope of any single company or university; the key to AETIONOMY’s success will be the broad nature of the project consortium, which brings together pharmaceutical companies, universities, and two patient groups, and boasts expertise in neurodegenerative diseases, molecular biology, clinical research, research ethics, data modelling and simulation, data standards, and patient involvement in research.

The new project will deliver data, tools and recommendations that can be used by the biomedical community and regulators to develop and approve new treatments and diagnostic tests.

For example, the new classification will help drug companies identify the most promising targets for new drugs and, crucially, the patients mostly likely to benefit from any resulting medicines.

An urgent need for new treatments

There are currently no drugs capable of curing Alzheimer’s or Parkinson’s diseases, and the few treatments designed to alleviate symptoms are not effective in all patients. By identifying sub-groups of patients based on the underlying, molecular cause of their disease, AETIONOMY will usher in a new era of personalised medicine, in which patients’ treatments will be determined on the basis of the cause of their disease, not its effects.

Achievements & News

IMI projects working on a new way of defining diseases
The work of IMI’s PRECISESADS and AETIONOMY projects on disease taxonomy is spotlighted in a new Nature Reviews Discovery comment piece. Currently, most diseases are still defined largely on the basis of their symptoms, yet while two patients may share the same diagnosis, the underlying causes of their symptoms may be very different. ###This means that a treatment that works in one patient may prove ineffective in another. The AETIONOMY and PRECISESADS projects are pioneering a new approach to the classification of disease; for AETIONOMY, in the field of Alzheimer’s and Parkinson’s diseases, and for PRECISESADS, in the field of systemic autoimmune diseases (such as rheumatoid arthritis and lupus). Although the projects are tackling the problem in different ways, their overall goal is the same: to pave the way towards a new taxonomy of disease that is based on the underlying causes of disease. In the long term, this will help to diagnose patients more accurately and provide them with a treatment that works for them.
(February 2015)

IMI scientist wins entrepreneurship award
The 2013 award for Hungarian Young Entrepreneur of the Year was won by Tamas Letoha, Chief Executive Officer of Pharmacoidea, which is a partner in two IMI projects: COMPACT and AETIONOMY. Tamas was selected as the winner from over ###400 public nominations from more than 50 small and medium-sized enterprises (SMEs) from a number of different business sectors. Dr Letoha, a medical researcher by training, received his award from the Hungarian Prime Minister, Viktor Orbán at the Role Model of the Year Award gala in January. The annual award is sponsored by the Role Model Foundation which was set up in 2013 to recognise successful Hungarian entrepreneurs under the age of 40. Tamas heads up Pharmacoidea Ltd. which specialises in R&D in drug discovery, functional food development and experimental cellular therapeutics against carcinomas. Tamas said that his achievements ‘were pretty much due to international R&D projects like AETIONOMY ’ and that he highly valued his connections with IMI.
(February 2014)

Participants Show participants on map

EFPIA companies
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Novartis Pharma AG, Basel, Switzerland
  • Sanofi-Aventis Research and Development, Chilly Mazarin, France
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Barcelonabeta Brain Research Center Foundation, Barcelona, Spain
  • Consorci Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München, Germany
  • Gottfried Wilhelm Leibniz Universitaet Hannover, Hannover, Germany
  • Institut du Cerveau et de la Moelle épinière, Paris, France
  • Karolinska Institutet, Stockholm, Sweden
  • Universitaetsklinikum Bonn, Bonn, Germany
  • Universite Du Luxembourg, Esch-sur-Alzette, Luxembourg
  • University College London, London, United Kingdom
  • Université d'Aix-Marseille, Marseille, France
Small and medium-sized enterprises (SMEs)
  • Pharmacoidea Fejleszto Es Szolgaltato Kft., Szeged, Hungary
  • Sc Neurorad SRL, Timisoara, Romania
Patient organisations
  • Alzheimer Europe, Luxembourg, Luxembourg
Third parties
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France
  • Institut des Neurosciences Translationnelles de Paris, Paris, France

CONTACT

Project coordinator
Phil Scordis
UCB Biopharma SPRL
+441753777187
Phil.Scordis[at]ucb.com
Managing entity
Martin Hofmann-Apitius
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
martin.hofmann-apitius[at]scai.fraunhofer.de